Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An instance of motor neuron disease that is caused by an inherited modification of the individual's genome.
Biomarker and diagnostic research for hereditary motor neuron disease has been reported in the published literature.
No approved treatments are currently available for hereditary motor neuron disease. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for hereditary motor neuron disease, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for hereditary motor neuron disease. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
No clinical trials have been registered for hereditary motor neuron disease.
192 publications have been identified in PubMed for hereditary motor neuron disease. Research spans Basic Science / Preclinical (48%), Review / Meta-Analysis (11%), and Epidemiology / Natural History (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 93 | 48% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 5:45 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Dynamine | Dynamine | Mayo Foundation | 1991 | — | Designated |
Gene therapy approaches for hereditary motor neuron disease have been reported in the published literature.
View trials for hereditary motor neuron disease
Research summaries
22 |
11% |
Disease patterns and progression | 22 | 11% |
Testing and diagnosis research | 21 | 11% |
New treatment approaches | 20 | 10% |
Clinical study results | 7 | 4% |
Patient case studies | 6 | 3% |
Other research | 1 | 1% |
Dashnaw CM (2026). [PMID: 41379813](https://pubmed.ncbi.nlm.nih.gov/41379813/). *ACS Chem Neurosci*. [Basic Science / Preclinical]
Carletta O (2026). [PMID: 40908789](https://pubmed.ncbi.nlm.nih.gov/40908789/). *Brain*. [Diagnostic / Biomarker]
Guo J (2026). [PMID: 40795306](https://pubmed.ncbi.nlm.nih.gov/40795306/). *Brain*. [Basic Science / Preclinical]
Pan Y (2026). [PMID: 40891024](https://pubmed.ncbi.nlm.nih.gov/40891024/). *Br J Pharmacol*. [Basic Science / Preclinical]
Perry CM (2026). [PMID: 41813136](https://pubmed.ncbi.nlm.nih.gov/41813136/). *The Journal of neuroscience : the official journal of the Society for Neuroscience*. [Basic Science / Preclinical]
Dabaj I (2026). [PMID: 41825231](https://pubmed.ncbi.nlm.nih.gov/41825231/). *Neurotherapeutics*. [Epidemiology / Natural History]
Alessandrini F (2026). [PMID: 41389796](https://pubmed.ncbi.nlm.nih.gov/41389796/). *Neuron*. [Gene Therapy / Novel Therapeutics]
Fioretti PV (2026). [PMID: 41004427](https://pubmed.ncbi.nlm.nih.gov/41004427/). *Brain*. [Basic Science / Preclinical]
González-Velasco Ó (2026). [PMID: 41378777](https://pubmed.ncbi.nlm.nih.gov/41378777/). *Brain*. [Basic Science / Preclinical]
González-Morales IJ (2026). [PMID: 42095821](https://pubmed.ncbi.nlm.nih.gov/42095821/). *Rev Med Inst Mex Seguro Soc*. [Review / Meta-Analysis]